Gene Therapy For Parkinson's Disease Global Market Report 2026

Description

Gene therapy for Parkinson's disease involves using genetic methods to insert, repair, or control genes within brain cells. It is intended to restore dopamine production, safeguard nerve cells, or fix mutations linked to the disease. The method aims to slow disease progression and offer long-lasting symptom relief.

The primary therapy types of gene therapy for Parkinson's disease are in vivo gene therapy and ex vivo gene therapy. In vivo gene therapy involves the direct administration of genetic material into the patient's body, usually via viral or non-viral vectors, to restore or enhance the function of specific genes associated with the progression of Parkinson's disease. These therapies focus on genes such as aromatic L-amino acid decarboxylase (AADC), glial cell line-derived neurotrophic factor (GDNF), neurturin, and other related genes, and are delivered through methods including intracerebral, intravenous, and other approaches. The main end-users include hospitals, specialty clinics, research institutes, and similar entities.

Tariffs are impacting the gene therapy for parkinson's disease market by increasing costs of imported viral vectors, specialized neurosurgical delivery devices, bioprocessing equipment, and quality control systems. Hospitals, research institutes, and therapy developers in North America and Europe are most affected due to reliance on imported high-precision tools, while Asia-Pacific faces increased production costs. These tariffs are raising therapy development expenses and slowing clinical deployment. However, they are also encouraging domestic vector manufacturing, regional clinical infrastructure investment, and localized production of gene therapy components.

The gene therapy for parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides gene therapy for parkinson's disease market statistics, including gene therapy for parkinson's disease industry global market size, regional shares, competitors with a gene therapy for parkinson's disease market share, detailed gene therapy for parkinson's disease market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy for parkinson's disease industry. This gene therapy for parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene therapy for parkinson's disease market size has grown exponentially in recent years. It will grow from $0.64 billion in 2025 to $0.81 billion in 2026 at a compound annual growth rate (CAGR) of 26.3%. The growth in the historic period can be attributed to advances in viral vector engineering, increased understanding of parkinson's disease pathology, expansion of neuroscience research funding, availability of improved delivery technologies, early clinical trial successes.

The gene therapy for parkinson's disease market size is expected to see exponential growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 26.0%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease therapies, rising adoption of personalized gene therapy approaches, expansion of late-stage clinical pipelines, growing demand for disease-modifying treatments, advancement of minimally invasive delivery techniques. Major trends in the forecast period include increasing development of viral vector-based therapies, rising focus on dopamine restoration approaches, growing use of neurotrophic factor gene delivery, expansion of precision intracerebral delivery methods, enhanced emphasis on long-term therapeutic efficacy.

The increasing focus on personalized medicine is expected to drive the growth of the gene therapy for Parkinson's disease market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies based on an individual's genetic profile, lifestyle, and environment. Interest in personalized medicine is rising due to the increasing demand for targeted therapies that enhance treatment efficacy while reducing adverse side effects. Gene therapy for Parkinson's disease within personalized medicine is employed to deliver customized genetic modifications that restore dopamine function and target patient-specific disease mechanisms. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, a significant increase from the 6 approvals in 2022. Consequently, the growing focus on personalized medicine is fueling the growth of the gene therapy for Parkinson's disease market.

Major companies are active in the gene therapy for Parkinson's disease market, concentrating on developing more targeted therapies, such as regenerative medicine advanced therapy, to support neuronal survival, restore dopamine function, and deliver long-lasting disease-modifying effects for patients with Parkinson's disease. Regenerative medicine advanced therapy (RMAT) refers to a special designation by the United States Food and Drug Administration (FDA) for regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, intended to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and review of promising therapies, was granted based on data provided by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, showing AB-1005's potential to slow disease progression and enhance motor function in Parkinson's patients.

In January 2025, BlackfinBio Limited, a UK-based company offering clinical-stage gene therapy solutions for rare neurological and dopamine-deficiency disorders, acquired the Parkinson's patent portfolio from Oxford Biomedica plc for an undisclosed amount. With this acquisition, BlackfinBio intends to advance its BFB-201 program for Parkinson's disease and utilize Oxford Biomedica's expertise in gene and cell therapy intellectual property to accelerate therapeutic development. Oxford Biomedica plc is a UK-based provider of gene and cell therapy development and vector technologies, contributing valuable intellectual property that complements BlackfinBio's initiatives.

Major companies operating in the gene therapy for parkinson's disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

North America was the largest region in the gene therapy for parkinson's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gene therapy for parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene therapy for parkinson's disease market consists of revenues earned by entities by providing services such as genetic counseling, preclinical studies, clinical trial management, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy for parkinson's disease market also includes sales of viral vectors, aromatic L-amino acid decarboxylase (AADC) gene therapy, glutamic acid decarboxylase (GAD) gene therapy, glial cell line-derived neurotrophic factor (GDNF) or neurturin-based neurotrophic therapies, and glucocerebrosidase (GBA)-targeted gene therapies. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Therapy For Parkinson's Disease Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gene therapy for parkinson's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene therapy for parkinson's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene therapy for parkinson's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Therapy Type: In Vivo Gene Therapy; Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors; Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC); Glial Cell Line-Derived Neurotrophic Factor (GDNF); Neurturin; Other Target Genes
4) By Delivery Method: Intracerebral; Intravenous; Other Delivery Methods
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors; Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy; Allogeneic Cell-Based Gene Therapy
Companies Mentioned: Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Eli Lilly and Company; Biogen Inc.; PTC Therapeutics Inc.; Zambon S.p.A.; Oxford BioMedica plc; Voyager Therapeutics Inc.; Insilico Medicine Inc.; Spur Therapeutics Inc.; Cerevance Inc.; MeiraGTx Holdings plc; BlackfinBio Inc.; Partner Therapeutics Inc.; Kenai Therapeutics Inc.; CureSen Therapeutics Inc.; BioVie Inc.; Clexio Biosciences Ltd.; Tetraneuron S.L.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MGTPD01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Gene Therapy For Parkinson's Disease Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Gene Therapy For Parkinson's Disease Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Gene Therapy For Parkinson's Disease Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Gene Therapy For Parkinson's Disease Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.5 Immersive Technologies (Ar/Vr/Xr)
4.2. Major Trends
- 4.2.1 Increasing Development Of Viral Vector-Based Therapies
- 4.2.2 Rising Focus On Dopamine Restoration Approaches
- 4.2.3 Growing Use Of Neurotrophic Factor Gene Delivery
- 4.2.4 Expansion Of Precision Intracerebral Delivery Methods
- 4.2.5 Enhanced Emphasis On Long-Term Therapeutic Efficacy

5. Gene Therapy For Parkinson's Disease Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Specialty Neurology Clinics
5.3 Research Institutes
5.4 Gene Therapy Developers
5.5 Academic Medical Centers

6. Gene Therapy For Parkinson's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Gene Therapy For Parkinson's Disease Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Gene Therapy For Parkinson's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Gene Therapy For Parkinson's Disease Market Size, Comparisons And Growth Rate Analysis
7.3. Global Gene Therapy For Parkinson's Disease Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Gene Therapy For Parkinson's Disease Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Gene Therapy For Parkinson's Disease Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Gene Therapy For Parkinson's Disease Market Segmentation

9.1. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
In Vivo Gene Therapy, Ex Vivo Gene Therapy
9.2. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Vector Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Viral Vectors, Non-Viral Vectors
9.3. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
9.4. Global Gene Therapy For Parkinson's Disease Market, Segmentation By Delivery Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intracerebral, Intravenous, Other Delivery Methods
9.5. Global Gene Therapy For Parkinson's Disease Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Research Institutes, Other End-Users
9.6. Global Gene Therapy For Parkinson's Disease Market, Sub-Segmentation Of In Vivo Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Viral Vectors, Non-Viral Vectors
9.7. Global Gene Therapy For Parkinson's Disease Market, Sub-Segmentation Of Ex Vivo Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

10. Gene Therapy For Parkinson's Disease Market Regional And Country Analysis

10.1. Global Gene Therapy For Parkinson's Disease Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Gene Therapy For Parkinson's Disease Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Gene Therapy For Parkinson's Disease Market

11.1. Asia-Pacific Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Gene Therapy For Parkinson's Disease Market

12.1. China Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Gene Therapy For Parkinson's Disease Market

13.1. India Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Gene Therapy For Parkinson's Disease Market

14.1. Japan Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Gene Therapy For Parkinson's Disease Market

15.1. Australia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Gene Therapy For Parkinson's Disease Market

16.1. Indonesia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Gene Therapy For Parkinson's Disease Market

17.1. South Korea Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Gene Therapy For Parkinson's Disease Market

18.1. Taiwan Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Gene Therapy For Parkinson's Disease Market

19.1. South East Asia Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Gene Therapy For Parkinson's Disease Market

20.1. Western Europe Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Gene Therapy For Parkinson's Disease Market

21.1. UK Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Gene Therapy For Parkinson's Disease Market

22.1. Germany Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Gene Therapy For Parkinson's Disease Market

23.1. France Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Gene Therapy For Parkinson's Disease Market

24.1. Italy Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Gene Therapy For Parkinson's Disease Market

25.1. Spain Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Gene Therapy For Parkinson's Disease Market

26.1. Eastern Europe Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Gene Therapy For Parkinson's Disease Market

27.1. Russia Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Gene Therapy For Parkinson's Disease Market

28.1. North America Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Gene Therapy For Parkinson's Disease Market

29.1. USA Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Gene Therapy For Parkinson's Disease Market

30.1. Canada Gene Therapy For Parkinson's Disease Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Gene Therapy For Parkinson's Disease Market

31.1. South America Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Gene Therapy For Parkinson's Disease Market

32.1. Brazil Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Gene Therapy For Parkinson's Disease Market

33.1. Middle East Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Gene Therapy For Parkinson's Disease Market

34.1. Africa Gene Therapy For Parkinson's Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Gene Therapy For Parkinson's Disease Market, Segmentation By Therapy Type, Segmentation By Vector Type, Segmentation By Target Gene, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Gene Therapy For Parkinson's Disease Market Regulatory and Investment Landscape

36. Gene Therapy For Parkinson's Disease Market Competitive Landscape And Company Profiles

36.1. Gene Therapy For Parkinson's Disease Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Gene Therapy For Parkinson's Disease Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Gene Therapy For Parkinson's Disease Market Company Profiles
- 36.3.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Gene Therapy For Parkinson's Disease Market Other Major And Innovative Companies

PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

38. Global Gene Therapy For Parkinson's Disease Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Gene Therapy For Parkinson's Disease Market

40. Gene Therapy For Parkinson's Disease Market High Potential Countries, Segments and Strategies

40.1 Gene Therapy For Parkinson's Disease Market In 2030 - Countries Offering Most New Opportunities
40.2 Gene Therapy For Parkinson's Disease Market In 2030 - Segments Offering Most New Opportunities
40.3 Gene Therapy For Parkinson's Disease Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer